MetLife’s group benefits segment posted adjusted earnings of $523 million in the third quarter of 2026, up 15% year over year, driven by favorable underwriting results across both life and disability lines. Sales are up 12% year-to-date, with growth in both national accounts and regional business. The segment has now delivered improving underwriting margins alongside genuine volume expansion for three consecutive quarters, an unusual convergence for a book this size, and one that has kept MetLife’s own mortality ratio below its 83%-to-88% target range all year.
MetLife’s Group Life mortality ratio has stayed below the company’s own 2026 target range of 83% to 88% for the entire year. In Q1, CFO John McCallion confirmed on the earnings call that the ratio was 80.1%. On the disability side, Q3 showed favorable claims experience as well, partially reversing the pressure the segment faced in prior periods.
MetLife’s own guidance assumes a 1% improvement in the group life mortality ratio translates to approximately $75 million in annual adjusted earnings, and that sensitivity runs in both directions. Group benefits has been the standout segment through the first half of the year, and Q3 extends a run that has now exceeded MetLife’s own target for three consecutive quarters.
A carrier running this well on underwriting has financial headroom to price more competitively, absorb marginal risk more comfortably, and invest in distribution.
The 12% year-to-date sales increase in group benefits matters as much as the underwriting result, because the two forces are pulling in the same direction. Volume growth is confirmed across both voluntary and core products, including dental, disability, life, and supplemental health. Ramy Tadros, MetLife’s regional president of US business, separately noted in October that the carrier is seeing strong persistency alongside new business momentum.
Tadros has also said publicly that employer demand for benefits consultative expertise is rising, particularly as healthcare cost pressure forces employers to scrutinize both benefits design and broker value more carefully. The 4% to 7% PFO growth MetLife guided for the full year is looking conservative. The group book is already running well ahead of that range after three quarters.
Net income for the quarter was $2.4 billion, up 187% from $818 million a year ago. That figure dominates the announcement but explains little about how the business actually performed. The swing was driven almost entirely by derivative accounting: a $929 million pre-tax net derivative loss in Q3 2025 flipped to a $698 million gain in Q3 2026, reflecting movements in US interest rates on embedded derivatives tied to ceded reinsurance.
Adjusted earnings, which strip out these swings, net investment gains and losses, and other market-driven items, rose 12% to $1.8 billion, and adjusted earnings per share excluding total notable items hit $2.85, the highest quarterly figure in MetLife’s history.
The adjusted return on equity, excluding total notable items, was 19.6% for the quarter, inside a rising-rate environment that simultaneously pushed GAAP book value per share down 22%. The decline reflects the fair value treatment of future policy benefits in a higher-rate environment, sitting in accumulated other comprehensive income and not reflecting any actual impairment of capital. Adjusted book value per share rose 5% to $59.41, and statutory adjusted capital is approximately $17 billion, up 3% from the prior quarter.
Elsewhere, the retirement and income solutions segment recovered in Q3 on the back of a sharp rebound in variable investment income, which reached $720 million pre-tax, well above the $600 million threshold MetLife had disclosed in September.
Adjusted earnings excluding notable items rose 12% to $478 million, though the reported figure of $413 million, down 6%, reflects a $65 million charge from the annual actuarial assumption review. Net income for the nine months ended September 30 was $4.2 billion. Adjusted earnings were $4.9 billion.
